Alkermes (NASDAQ: ALKS) Price Target Raised Amid Strong Financial Performance and Strategic Shift

Font: Financial Modeling Prep  • May 06, 2026

• Analyst firm Needham maintains its Buy rating for Alkermes (NASDAQ: ALKS), raising its price target to $50.00 from $45.00.
• The biotechnology company reported strong first-quarter revenues of $392.91 million, surpassing analyst estimates by 9.5%, and improved adjusted EBITDA of $80.30 million.
• Alkermes' strategic shift into neuroscience and sleep medicine, bolstered by the Avadel acquisition, is driving significant product sales and future growth projections.

On May 6, 2026, analyst firm Needham maintains its Buy rating for Alkermes (NASDAQ: ALKS), a leading biotechnology stock. Needham also raises its price target on the stock to $50.00 from $45.00. Alkermes is a pharmaceutical company strategically shifting its focus to become an an integrated neuroscience and sleep medicine business. This significant transition includes its recent acquisition of Avadel, highlighting its growth strategy.

The positive analyst rating follows strong financial results, underscoring Alkermes' robust market performance. As highlighted by Zacks, Alkermes posted revenues of $392.91 million for the first quarter, beating analyst estimates by 9.5%. This represents a significant increase from the $306.51 million in revenue from the same quarter a year ago, demonstrating strong top-line growth and a positive investment outlook.

While the company reported a loss of $0.40 per share, this result was better than expected. It beat the Zacks Consensus Estimate, which had projected a larger loss of $0.57 per share. This marks the fourth straight quarter where Alkermes has surpassed consensus estimates for both earnings and revenue, showcasing consistent financial discipline.

A key driver of this impressive performance is the company's product sales. Proprietary product sales rose to $338.10 million in the first quarter. The newly integrated drug LUMRYZ, stemming from the Avadel acquisition, contributed $39.50 million to this total, showing early success from the company's strategic shift and product pipeline strength.

Looking forward, management projects total revenues for 2026 between $1.73 billion and $1.84 billion. The company also anticipates that four of its commercial products will each generate over $300 million in annual net sales. The company's adjusted EBITDA, a crucial measure of profitability, improved to $80.30 million for the quarter, reflecting enhanced operational efficiency.